Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass

A. Marc Gillinov, Patrick A. DeValeria, Jerry A. Winkelstein, Ian Wilson, William E. Curtis, David Shaw, C. Grace Yeh, Alfred R. Rudolph, William A. Baumgartner, Ahvie Herskowitz, Duke E. Cameron

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Although complement activation during cardiopulmonary bypass (CPB) is well documented, its pathogenic role in postperfusion organ injury is unproven. In this study, soluble human complement receptor type 1 (sCR1), a potent inhibitor of complement activation, was used to determine the contribution of complement activation to pulmonary injury in a porcine model of CPB. In vitro experiments demonstrated that sCR1 inhibits both classic and alternative complement pathways in the pig. Seven control piglets and 6 piglets treated with sCR1 (12 mg/kg intravenously) underwent 2 hours of hypothermic (28 °C) CPB followed by 2 hours of observation. In control piglets, total hemolytic complement activity and functional activities of C3 and C5 declined to 61.3%, 67.8%, and 61.4% of prebypass values, respectively, after 2 hours of CPB. Plasma from animals treated with sCR1 had virtually no hemolytic activity (total hemolytic complement activity < 5% of baseline), demonstrating effective complement inhibition. Similar degrees of neutropenia developed in the two groups during CPB, and there was no difference in post-CPB lung tissue myeloperoxidase level. Two hours after CPB, pulmonary vascular resistance increased 338% in control piglets but only 147% in piglets pretreated with sCR1 (p < 0.05); the alveolar-arterial gradient was not significantly different between controls (331 ± 52 mm Hg) and piglets receiving sCR1 (290 ± 85 mm Hg), Histologic examination revealed similar degrees of pulmonary edema in both groups. These data constitute direct evidence that complement activation plays a pathogenic role in lung injury after CPB. Although pretreatment with sCR1 ameliorated lung injury after CPB, resulting in decreased pulmonary hypertension, complement inhibition did not improve post-CPB oxygenation and had no significant effect on leukocyte kinetics or lung histology. Thus, complement participates in the pathogenesis of lung injury after CPB, but is not responsible for all of the pulmonary damage.

Original languageEnglish (US)
Pages (from-to)619-624
Number of pages6
JournalThe Annals of Thoracic Surgery
Volume55
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Complement Receptors
Cardiopulmonary Bypass
Complement Activation
Lung Injury
Complement Hemolytic Activity Assay
Lung
Swine
Alternative Complement Pathway
Pulmonary Edema
Neutropenia
Pulmonary Hypertension
Vascular Resistance
Peroxidase
Histology
Leukocytes
Observation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Gillinov, A. M., DeValeria, P. A., Winkelstein, J. A., Wilson, I., Curtis, W. E., Shaw, D., ... Cameron, D. E. (1993). Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. The Annals of Thoracic Surgery, 55(3), 619-624. https://doi.org/10.1016/0003-4975(93)90264-I

Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. / Gillinov, A. Marc; DeValeria, Patrick A.; Winkelstein, Jerry A.; Wilson, Ian; Curtis, William E.; Shaw, David; Yeh, C. Grace; Rudolph, Alfred R.; Baumgartner, William A.; Herskowitz, Ahvie; Cameron, Duke E.

In: The Annals of Thoracic Surgery, Vol. 55, No. 3, 1993, p. 619-624.

Research output: Contribution to journalArticle

Gillinov, AM, DeValeria, PA, Winkelstein, JA, Wilson, I, Curtis, WE, Shaw, D, Yeh, CG, Rudolph, AR, Baumgartner, WA, Herskowitz, A & Cameron, DE 1993, 'Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass', The Annals of Thoracic Surgery, vol. 55, no. 3, pp. 619-624. https://doi.org/10.1016/0003-4975(93)90264-I
Gillinov, A. Marc ; DeValeria, Patrick A. ; Winkelstein, Jerry A. ; Wilson, Ian ; Curtis, William E. ; Shaw, David ; Yeh, C. Grace ; Rudolph, Alfred R. ; Baumgartner, William A. ; Herskowitz, Ahvie ; Cameron, Duke E. / Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. In: The Annals of Thoracic Surgery. 1993 ; Vol. 55, No. 3. pp. 619-624.
@article{02337ce0d70641e9a8898e2f15e1451b,
title = "Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass",
abstract = "Although complement activation during cardiopulmonary bypass (CPB) is well documented, its pathogenic role in postperfusion organ injury is unproven. In this study, soluble human complement receptor type 1 (sCR1), a potent inhibitor of complement activation, was used to determine the contribution of complement activation to pulmonary injury in a porcine model of CPB. In vitro experiments demonstrated that sCR1 inhibits both classic and alternative complement pathways in the pig. Seven control piglets and 6 piglets treated with sCR1 (12 mg/kg intravenously) underwent 2 hours of hypothermic (28 °C) CPB followed by 2 hours of observation. In control piglets, total hemolytic complement activity and functional activities of C3 and C5 declined to 61.3{\%}, 67.8{\%}, and 61.4{\%} of prebypass values, respectively, after 2 hours of CPB. Plasma from animals treated with sCR1 had virtually no hemolytic activity (total hemolytic complement activity < 5{\%} of baseline), demonstrating effective complement inhibition. Similar degrees of neutropenia developed in the two groups during CPB, and there was no difference in post-CPB lung tissue myeloperoxidase level. Two hours after CPB, pulmonary vascular resistance increased 338{\%} in control piglets but only 147{\%} in piglets pretreated with sCR1 (p < 0.05); the alveolar-arterial gradient was not significantly different between controls (331 ± 52 mm Hg) and piglets receiving sCR1 (290 ± 85 mm Hg), Histologic examination revealed similar degrees of pulmonary edema in both groups. These data constitute direct evidence that complement activation plays a pathogenic role in lung injury after CPB. Although pretreatment with sCR1 ameliorated lung injury after CPB, resulting in decreased pulmonary hypertension, complement inhibition did not improve post-CPB oxygenation and had no significant effect on leukocyte kinetics or lung histology. Thus, complement participates in the pathogenesis of lung injury after CPB, but is not responsible for all of the pulmonary damage.",
author = "Gillinov, {A. Marc} and DeValeria, {Patrick A.} and Winkelstein, {Jerry A.} and Ian Wilson and Curtis, {William E.} and David Shaw and Yeh, {C. Grace} and Rudolph, {Alfred R.} and Baumgartner, {William A.} and Ahvie Herskowitz and Cameron, {Duke E.}",
year = "1993",
doi = "10.1016/0003-4975(93)90264-I",
language = "English (US)",
volume = "55",
pages = "619--624",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass

AU - Gillinov, A. Marc

AU - DeValeria, Patrick A.

AU - Winkelstein, Jerry A.

AU - Wilson, Ian

AU - Curtis, William E.

AU - Shaw, David

AU - Yeh, C. Grace

AU - Rudolph, Alfred R.

AU - Baumgartner, William A.

AU - Herskowitz, Ahvie

AU - Cameron, Duke E.

PY - 1993

Y1 - 1993

N2 - Although complement activation during cardiopulmonary bypass (CPB) is well documented, its pathogenic role in postperfusion organ injury is unproven. In this study, soluble human complement receptor type 1 (sCR1), a potent inhibitor of complement activation, was used to determine the contribution of complement activation to pulmonary injury in a porcine model of CPB. In vitro experiments demonstrated that sCR1 inhibits both classic and alternative complement pathways in the pig. Seven control piglets and 6 piglets treated with sCR1 (12 mg/kg intravenously) underwent 2 hours of hypothermic (28 °C) CPB followed by 2 hours of observation. In control piglets, total hemolytic complement activity and functional activities of C3 and C5 declined to 61.3%, 67.8%, and 61.4% of prebypass values, respectively, after 2 hours of CPB. Plasma from animals treated with sCR1 had virtually no hemolytic activity (total hemolytic complement activity < 5% of baseline), demonstrating effective complement inhibition. Similar degrees of neutropenia developed in the two groups during CPB, and there was no difference in post-CPB lung tissue myeloperoxidase level. Two hours after CPB, pulmonary vascular resistance increased 338% in control piglets but only 147% in piglets pretreated with sCR1 (p < 0.05); the alveolar-arterial gradient was not significantly different between controls (331 ± 52 mm Hg) and piglets receiving sCR1 (290 ± 85 mm Hg), Histologic examination revealed similar degrees of pulmonary edema in both groups. These data constitute direct evidence that complement activation plays a pathogenic role in lung injury after CPB. Although pretreatment with sCR1 ameliorated lung injury after CPB, resulting in decreased pulmonary hypertension, complement inhibition did not improve post-CPB oxygenation and had no significant effect on leukocyte kinetics or lung histology. Thus, complement participates in the pathogenesis of lung injury after CPB, but is not responsible for all of the pulmonary damage.

AB - Although complement activation during cardiopulmonary bypass (CPB) is well documented, its pathogenic role in postperfusion organ injury is unproven. In this study, soluble human complement receptor type 1 (sCR1), a potent inhibitor of complement activation, was used to determine the contribution of complement activation to pulmonary injury in a porcine model of CPB. In vitro experiments demonstrated that sCR1 inhibits both classic and alternative complement pathways in the pig. Seven control piglets and 6 piglets treated with sCR1 (12 mg/kg intravenously) underwent 2 hours of hypothermic (28 °C) CPB followed by 2 hours of observation. In control piglets, total hemolytic complement activity and functional activities of C3 and C5 declined to 61.3%, 67.8%, and 61.4% of prebypass values, respectively, after 2 hours of CPB. Plasma from animals treated with sCR1 had virtually no hemolytic activity (total hemolytic complement activity < 5% of baseline), demonstrating effective complement inhibition. Similar degrees of neutropenia developed in the two groups during CPB, and there was no difference in post-CPB lung tissue myeloperoxidase level. Two hours after CPB, pulmonary vascular resistance increased 338% in control piglets but only 147% in piglets pretreated with sCR1 (p < 0.05); the alveolar-arterial gradient was not significantly different between controls (331 ± 52 mm Hg) and piglets receiving sCR1 (290 ± 85 mm Hg), Histologic examination revealed similar degrees of pulmonary edema in both groups. These data constitute direct evidence that complement activation plays a pathogenic role in lung injury after CPB. Although pretreatment with sCR1 ameliorated lung injury after CPB, resulting in decreased pulmonary hypertension, complement inhibition did not improve post-CPB oxygenation and had no significant effect on leukocyte kinetics or lung histology. Thus, complement participates in the pathogenesis of lung injury after CPB, but is not responsible for all of the pulmonary damage.

UR - http://www.scopus.com/inward/record.url?scp=0027480505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027480505&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(93)90264-I

DO - 10.1016/0003-4975(93)90264-I

M3 - Article

C2 - 8383955

AN - SCOPUS:0027480505

VL - 55

SP - 619

EP - 624

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -